Eterna Capex To Revenue from 2010 to 2024
| ERNA Stock | USD 0.29 0.03 9.38% |
Capex To Revenue | First Reported 2010-12-31 | Previous Quarter 0.25 | Current Value 0.26 | Quarterly Volatility 0.10142199 |
Check Eterna Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eterna Therapeutics' main balance sheet or income statement drivers, such as Total Revenue of 64.6 K, Other Operating Expenses of 20 M or Total Operating Expenses of 19.3 M, as well as many indicators such as Price To Sales Ratio of 133, Dividend Yield of 0.0018 or PTB Ratio of 4.42. Eterna financial statements analysis is a perfect complement when working with Eterna Therapeutics Valuation or Volatility modules.
Eterna | Capex To Revenue |
Latest Eterna Therapeutics' Capex To Revenue Growth Pattern
Below is the plot of the Capex To Revenue of Eterna Therapeutics over the last few years. It is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. Eterna Therapeutics' Capex To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eterna Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Capex To Revenue | 10 Years Trend |
|
Capex To Revenue |
| Timeline |
Eterna Capex To Revenue Regression Statistics
| Arithmetic Mean | 0.13 | |
| Geometric Mean | 0.10 | |
| Coefficient Of Variation | 76.92 | |
| Mean Deviation | 0.09 | |
| Median | 0.07 | |
| Standard Deviation | 0.10 | |
| Sample Variance | 0.01 | |
| Range | 0.2418 | |
| R-Value | 0.79 | |
| Mean Square Error | 0 | |
| R-Squared | 0.62 | |
| Significance | 0.0005 | |
| Slope | 0.02 | |
| Total Sum of Squares | 0.14 |
Eterna Capex To Revenue History
About Eterna Therapeutics Financial Statements
Eterna Therapeutics stakeholders use historical fundamental indicators, such as Eterna Therapeutics' Capex To Revenue, to determine how well the company is positioned to perform in the future. Although Eterna Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Eterna Therapeutics' assets and liabilities are reflected in the revenues and expenses on Eterna Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Eterna Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Capex To Revenue | 0.25 | 0.26 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Eterna Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eterna Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eterna Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eterna Therapeutics Stock:Check out the analysis of Eterna Therapeutics Correlation against competitors. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.31) | Revenue Per Share 0.03 | Return On Assets (0.29) | Return On Equity (11.54) |
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.